诺诚健华(09969.HK) 今日(28日)午后最新报12元,升5.08%,成交391.05万股,涉资4,628.55万元。高盛发表研究报告指,诺诚健华今年第三季药物销售5.31亿元人民币(下同),按年升39%,大致符合该行预期的5.48亿元,主要受奥布替尼持续放量带动,包括一线CLL/SLL纳入国家医保目录后的贡献,以及MZL的差异化贡献。总收入达9.62亿元,按年升150%,高于该行预期,主要...
Source Link诺诚健华(09969.HK) 今日(28日)午后最新报12元,升5.08%,成交391.05万股,涉资4,628.55万元。高盛发表研究报告指,诺诚健华今年第三季药物销售5.31亿元人民币(下同),按年升39%,大致符合该行预期的5.48亿元,主要受奥布替尼持续放量带动,包括一线CLL/SLL纳入国家医保目录后的贡献,以及MZL的差异化贡献。总收入达9.62亿元,按年升150%,高于该行预期,主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.